Phesi Introduces ClinSite™ Clinical Trial Investigator Site Selection Tool

July 29, 2019 11:30 UTC

EAST LYME, Conn.--(BUSINESS WIRE)-- Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced the launch of ClinSite, a self-service, artificial intelligence (AI)-powered tool that enables biopharmaceutical companies to search for and select top-performing investigator trial sites for clinical trials in all therapeutic areas, including rare diseases.

This press release features multimedia. View the full release here:

ClinSite, a Software as a Service (SaaS) solution that incorporates natural language processing and machine learning, is an evolution of the technology Phesi patented in 2007 and fully automated in 2018. Phesi’s technology platform incorporates data from 4.2 million physicians and 600,000 investigator sites, identified from 80,000 sources and 330,000 clinical trials in 240 countries, and growing. Investigator sites selected through this platform in more than 250 clinical trials have enrolled up to 40% faster than other sites, saving millions of dollars per trial.

“Many companies own large databases, but it’s what Phesi can do with the data that sets us apart,” said Gen Li, Phesi founder and president. “ClinSite isn’t just an investigator site search engine; it also updates, cleans, and structures millions of data points automatically and in real-time, for easy filtering and analysis by the users. Phesi’s algorithms combine data and model ’what if‘ scenarios, enabling clinical trial sponsors and designers to make well-informed and quick decisions – saving precious time and money in getting new therapies to patients.”

Poor investigator site selection often results in low patient recruitment, prolonged trial timelines, and unreliable data. A recent analysis of 761 clinical trials from Phesi’s database showed that 30% of Phase 3 trials experienced a delay of at least three months.1 Such a delay can have tremendous financial ramifications, considering recently published data estimating the median cost of a Phase 3 clinical trial at $19 million (range: $12.2 million to $33.1 million), and a per-patient cost of $44,117.2

“It is nearly impossible to gauge investigator site performance, one of the main reasons for poor site selection when using traditional trial planning methods,” said Steve Arlington, life sciences executive and entrepreneur and a Phesi board member. “Using an AI-driven tool like ClinSite enables sponsors to automatically compare relevant trials and pinpoint global sites with the right expertise and proven performance for a given protocol design in any therapeutic area. With new technology, enrollment delays due to site selection should no longer be acceptable.”

Phesi will announce the hiring of a chief commercial officer to commercialize ClinSite in the next few weeks. In 2020, the company also plans to introduce a fully integrated module that will help trial sponsors optimize design of study protocols — another issue that underlies many recruitment delays.

Click here to request a live demonstration of the ClinSite platform.

About Phesi

Phesi provides comprehensive clinical development analytical products and services for biopharmaceutical companies around the world. The company’s integrated offerings cover the entire clinical development process — from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management. Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools, consisting of 330,000 completed clinical trials, 604,000 completed research projects, 4.2 million physicians and 1.8 million investigator records.

For more information please visit Click here to read our blog, and follow Phesi on LinkedIn and Twitter.


  1. Data on file. Phesi.
  2. Moore TJ. Zhang H, Anderson G. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine. 2018;178(11):1451-1457.



Reba Auslander
RAliance Communications


Source: Phesi

Smart Multimedia Gallery

View this news release and multimedia online at:

Back to news